I think I recall GNW is the 4th leading mortgage provider with 16.7% of the US market. The top 4 were lumped very closely together. The 5th margest provider was about 6%. It was very bullish!
Shut up you bumbling idiot. You the only person I see thinks it's an accomplishment that Russ and the boys have TGB at 62 CENTS!
So you are saying if an injector was easier to administer but not identical the FDA will not approve? I think this has been somewhat address already with MYL.. Not with the injector but that it doesn't have to be identical. Remember the citizens petition?
Well home care will can be more costly than an institution but it all depends on how much care the insured needs. Twenty four hour round the clock care at home is much more expensive, but the person that only needs 4-6 hours a day it's a whole lot less expensive.
Tappy, I was at the ASM and forgot to ask a question on my list. Mark Chapman already brought it up on his latest article. In regards to QST, why wasn't a control group used? I sent an email to Jack asking this and he has yet to respond. If there is a CRL or some delay due to this then they all need to be fired!
I'm just doing some DD on MNKD but one thing I see thus far is you are a LOUD mouth Short! Now I will continue to study this!
And bought HL and ASM. Should have bought MUX. MUX is about the most friendly shareholder company I've ever owned. I hate this deal the management did with GPL. The deal will definitely but an anchor on the PPS.
Perhaps GPL is somewhat overvalued. I owned GPL but sold a few months ago and bought ASM. ASM just looks more appealing on a value basis.
Dude you are such a joke. I don't mind you bringing out the failures of ATRS cause there are many. You however was recently pumping it like a 16 year old on a las Vegas call girl. Just get lost!
SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced that it has received a Complete Response Letter (“CRL”) from the United States Food and Drug Administration (“FDA”) regarding its New Drug Application (“NDA”) for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.